JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product Toripalimab Injection (brand name: Tuoyi®, product code: JS001) and Angoriximab Injection (brand name: Junshida®, product code: JS002) have been successfully included in the National Reimbursement Drug List (NRDL) for 2025 under Category B. The updated NRDL will take effect on January 1, 2026.

As of the announcement date, all four of the company’s commercialized products—Tuoyi®, Adalimumab Injection (brand name: Junmaikang®, product code: UBP1211), Deuremidevir Hydrobromide Tablets (brand name: Mindewei®, product code: VV116/JT001), and Junshida®—have been included in the NRDL.

Tuoyi® now covers all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the NRDL for treating renal cell carcinoma, triple-negative breast cancer, and melanoma. Junshida®, included for the first time, is the only domestically developed PCSK9-targeted drug in the updated NRDL for statin-intolerant patients.